Proliferative Glomerulonephritis with Monoclonal Igg Deposits

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2025-09-16
Clinical Trial Update: Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits [Phase 2]
Phase 2 clinical trial evaluating daratumumab for proliferative glomerulonephritis with monoclonal IgG deposits is currently recruiting.